The American Heart Association (AHA) published guidelines for treatment of resistant hypertension in 2008 recommending use of thiazide diuretics (particularly chlorthalidone), aldosterone antagonists, and fixed-dose combination medications, but it is unclear the extent to which these guidelines are being followed. OBJECTIVE: To describe trends in physician use of recommended medications for resistant hypertension and assess variations in medication use based on geography, physician specialty and patient characteristics. DESIGN: Cross-sectional analysis using the National Ambulatory Medical Care Survey from 2006 to 2010. STUDY SAMPLE: We analyzed visits of hypertension patients to family physicians, general internists, and cardiologists. Resistant hypertension was defined as concurrent use of ≥ 4 classes of blood pressure (BP) medications or elevated BP despite the use of ≥ 3 medications. Pregnant patients and visits with diagnosed heart failure or end-stage renal disease were excluded. MAIN OUTC OME: U se of A HA-r ec ommen d ed medications for management of resistant hypertension. RESULTS: Of 19,500 patient visits with hypertension, 1,567 or 7.1 % CI (6.6-7.7 %) met criteria for resistant hypertension. Thiazide diuretic use was reported in 58.9 % of visits pre-guidelines vs. 54.8 % postguidelines (p=0.37). Use of aldosterone antagonists was low and also did not change significantly after guideline publication (3.1 % vs. 4.5 %, p=0.27). Fixeddose combinations use was 42.0 % before and 37 % after guideline publication (p = 0.29). Each 10-year increase in patient age was associated with lower thiazide use (OR 0.87,, as was presence of comorbid ischemic heart disease (OR 0.62, CI 0.41-0.94). Medication use did not vary by geography or physician specialty. CONCLUSION: Use of AHA-recommended medications for resistant hypertension remains low after publication of guidelines. Healthcare systems should encourage more frequent prescribing of these medications to improve care in this high-risk population.
INTRODUCTION
According to recent observational studies of national data, an estimated 8.9 % to 11.4 % of US hypertensive adults have resistant hypertension, 1,2 defined by blood pressure (BP) that remains above goal despite concomitant use of ≥ 3 distinct classes of antihypertensive medications or requiring ≥ 4 medications to achieve BP control with the medication regimen ideally including a thiazide diuretic. 3 Data from clinical trials suggest that the prevalence may be substantially higher and the incidence rate among all hypertensive adults has been reported at 1.9 % per year. 4 In 2008, the American Heart Association (AHA) published guidelines for treatment of resistant hypertension that included recommendations for optimal diuretic use (chlorthalidone as the preferred thiazide diuretic), adding an aldosterone antagonist as a fourth medication for uncontrolled BP, and using fixed-dose combination drugs. 3 According to these guidelines, most resistant hypertension patients should be treated with an appropriately dosed thiazide diuretic, calcium channel blocker (CCB), and an ACE inhibitor (ACE-I) or angiotensin receptor blocker (ARB) with aldosterone antagonists as the first choice for patients whose BP remains uncontrolled on optimal doses of ≥ 3 distinct classes of antihypertensive medications. Beta blockers are indicated in the setting of ischemic heart disease (IHD) or congestive heart failure (CHF).
These therapeutic maneuvers have been shown to achieve greater rates of BP control among patients with hypertension, but it is unclear how often they are used in practice. [5] [6] [7] [8] [9] [10] The National Ambulatory Medical Care Survey
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(NAMCS), an annual nationally representative sample of office visits in the US, collects blood pressure measurements, diagnoses and medications. We sought to assess the prevalence of resistant hypertension among office visits to physicians who typically manage hypertension, describe trends in physicians' use of recommended medications 2 years after publication of the AHA guidelines, and determine whether use of recommended medications varied by regional-level, physician-level, or patient-level characteristics. 11 Although European Guidelines on Hypertension discuss use of aldosterone antagonist for resistant hypertension, 12 other major guidelines in Canada, Australia, and US (the Joint National Commission JNC VII) do not include explicit recommendations for resistant hypertension.
METHODS

Data and Study Design
NAMCS is an annual, nationally representative crosssectional survey of ambulatory office visits to physicians in the US that uses a multi-stage probability sampling design to represent all visits to non-federally employed office-based physicians engaged in direct patient care. The sampling design includes probability sampling of defined geographic areas, physician practices within those areas, and patient visits within each practice. Individuals are not followed longitudinally and are extremely unlikely to contribute multiple visits across different survey years. A more detailed description of NAMCS methodology is available from the National Center for Health Statistics (NCHS).
13-17
Study Sample
We used NAMCS survey data from 2006-2010 and included all patient visits in which the patient was at least 18 years old, had a history of hypertension, was seen by a physician who can reasonably be expected to routinely manage hypertension (general/family practitioners, internists, and cardiologists), and had a recorded BP for the visit. NAMCS was not designed to sample visits to nephrologists systematically, so these visits were not included in this analysis. We excluded visits in which the patient was specified as pregnant, or had a positive pregnancy test that visit.
To avoid misclassification of resistant hypertension, we also excluded patients with CHF (defined by a "yes" answer to "Does the patient now have a history of heart failure?") and end-stage renal disease (ESRD) defined by ICD-9 5859, or being on dialysis (identified by procedure code V4511 or dialysis listed as the reason for visit) . Patients with CHF are often on multiple antihypertensive medications for reasons other than BP management. ESRD is associated with dialysis-related fluctuations in BP and electrolyte disturbances that impact therapeutic decisions for BP management.
Patient and Visit Characteristics
Patient demographic and visit characteristics were abstracted from the medical record by the physician, physician staff, or census bureau staff. 15 Age, race, and gender, as well as the number of medications added or continued by the physician at the visit were recorded. Office BP was ascertained by routine measurements without specifications for BP cuff size or number of repeated measurements. We also identified visits associated with diagnoses of comorbid conditions such as IHD and diabetes (DM). Practice setting characteristics are also recorded, including type of practice (private, community health center, other) and geographic region. Finally, we also included physician specialty (general/family physician, internal medicine, and cardiology).
To identify BP medications, we reviewed the Multum Lexicon database used by NAMCS for coding medications. 18 We identified antihypertensive drug classes and then reviewed specific medication names to ensure that they are medications likely used for the purpose of BP management. See the Appendix Online for the list, by class, of medications we defined as antihypertensive medications. NAMCS reported medications as either continued or newly prescribed during the visit. Medications reported as continued were considered to be the patient's medication regimen prior to the visit.
In order to identify visits that met criteria for resistant hypertension at presentation to the office, we defined resistant hypertension as visits reporting ≥ 4 distinct classes of continued BP medications, or an elevated BP (≥ 140/ 90 mmHg) despite ≥ 3 continued medications with at least one first-line medication (thiazide, ACE-I, ARB, or CCB) included in the medication list. When describing prevalent use of medications, we considered those medications that were continued or that were newly added at the visit.
Statistical Analysis
We first described the prevalence of resistant hypertension and then used chi-square tests to compare physician use of recommended BP medications before and after 2008. Since the use of recommended medications may be different among those patients who present with uncontrolled BP, we also assessed trends in medication use among resistant hypertension visits with uncontrolled BP. We used linear regressions with visit year as a continuous predictor variable to test for linear trends. Finally, we conducted bivariate and multivariate logistic regressions to examine characteristics associated with use of recommended medications. We compared the use of thiazide diuretics by physician-level and patient-level characteristics. The multivariate model included all covariates with P values ≤ 0.10 from bivariate analyses in addition to sex and race. NCHS considers an estimate to be reliable if it has a relative standard error (RSE) of 30 %, and estimates based on fewer than 30 records are considered unreliable. 19 Variables with sample observations of < 30 or RSE > 0.3 were excluded from the model. Analyses to assess variations in use of aldosterone antagonist and chlorthalidone were not feasible because the sample sizes of observed visits reporting their use were too small. NAMCS records a maximum of eight medications; we performed a sub-analysis excluding visits reporting eight continued medications, to account for possible differential omission of BP medications and the inability to assess additional (i.e., ninth) medications prescribed at these visits.
We conducted all analyses using Stata 12 (StataCorp, College Station, Texas) applying survey weights to account for NAMCS' complex sampling design and obtain population estimates.
RESULTS
NAMCS 2006-2010 included 154,421 observed visits representing 4.9 billion outpatient visits. A total of 19,500 observed visits of hypertensive adult patients met our criteria for inclusion, while 1,567 visits met our definition for resistant hypertension, comprising 7.1 % (95 % CI 6.5-7.7) of patient visits with hypertension ( Fig. 1) . Patients with resistant hypertension were elderly (mean age 68 years) and had a high prevalence of comorbid conditions like DM (35.2 % CI 31.7-38.9) and IHD (17.7 %). Over threequarters of the visits with resistant hypertension (78.3 % CI 75.4-80.9) had recorded BPs that were uncontrolled (Table 1) .
Medication Use
On average, patients were taking 6.1 total medications (SD 2.0) and 3.5 distinct classes of antihypertensive medications (SD 0.6), with no significant change in total numbers of medication used over the observation period from 2006 to 2010 (p for trend 0.32). The two most commonly used classes of antihypertensive medications in resistant hypertension were diuretics and beta blockers. Thiazide diuretic use was reported at 56.4 % (CI 52.9-59.8) of visits and 1.2 % of visits recorded use of chlorthalidone (CI 0.3-2.0). Aldosterone antagonist therapy was used at only 3.6 % (CI 2.4-4.5) of visits. We did not observe any statistically significant change in use of thiazides (54.8 % vs. 58.9 %), chlorthalidone (1.4 % vs. 1.6 %), aldosterone antagonists (4.5 % vs. 3.1 %), or fixeddose combination (37.2 % vs. 42.0 %) in the period following publication of the AHA guidelines as compared with the period prior to publication (Table 2) .
Among visits with uncontrolled BP (N = 1,225), medication use following the AHA guidelines was similarly unchanged (Table 2) . Chlorthalidone and aldosterone antagonist use remained low throughout the 5-year period (<3 % and <4 % of visits surveyed, respectively) among these visits with uncontrolled hypertension. No significant change in use of thiazide diuretics or fixed-dose combinations was observed, [Fig. 2 ] but use of ACE inhibitors decreased by an absolute difference of 4.7 % after 2008 while calcium channel blocker (58.6 % vs. 64.3 %) and beta blocker use (70.9 % vs. 77.1 %) trended upward without reaching statistical significance ( Table 2 ).
Predictors of Thiazide Use
In bivariate analyses, use of thiazide diuretics was associated with older age, absence of comorbid ischemic heart disease, use of fixed-dose combinations, and visits to a non-cardiologist. In multivariate regression, every 10-year increase in age was associated with 13 % lower odds of thiazide use (OR 0.87, CI 0.77-0.97). Use of fixed-dose combinations was associated with higher thiazide use (OR 5.04, CI 3.51-7.25). Comorbid IHD was associated with lower use of thiazides (OR 0.62, CI 0.41-0.94). Medicaid was associated with lower use of thiazide diuretics (OR 0.36, CI 0.16-0.78) as compared to private insurance, although interpretation is limited due to small sample size of Medicaid visits. Use of thiazide diuretics did not vary significantly by geographic region, clinic type, physician specialty, race or gender (Table 3) . Because thiazides are commonly used in combination medications, we repeated the analysis excluding fixed-dose combinations from the model. The magnitude and direction of our results for the other significant predictors did not change.
DISCUSSION
In our analysis of a nationally representative sample of office-based visits in the United States, we found that US physicians' treatment of resistant hypertension during office visits was not consistent with recommended guidelines. While overall diuretic use was common, thiazides were used in under 60 % of these visits, fixed dose combination in only 40 %, and use of aldosterone antagonists and chlorthalidone was extremely uncommon. These low usage patterns persisted through 2010, two years after the publication of AHA guidelines for the management of resistant hypertension and unchanged from the period prior to publication of these guidelines.
Few prior studies describe how physicians manage resistant hypertension in the United States. Our finding of 7.1 % prevalence of resistant hypertension among visits 2 The small difference could be explained by the differing study periods, differences in population-based versus clinic based samples, as well as differences in selfreported medication use in NHANES versus clinically recorded medication use in NAMCS. While resistant hypertension accounts for a modest proportion of all ambulatory visits in the US, our analyses demonstrate that these visits with resistant hypertension are not rare occurrences and the low adherence with guidelines suggests existing opportunities for physicians to improve BP control.
NAMCS offers the advantage of assessing the number of concurrent medications used and describes physician prescribing behavior at the point of care. Our data suggest that physicians underutilized effective medications even when facing uncontrolled hypertension refractory to multiple medications. This underutilization is also consistent with previous findings. The NHANES analysis reported low use of aldosterone antagonists (3 %). 2 A study of pharmaceutical and claims data reported a 5.9 % use of aldosterone antagonists and 3 % use of chlorthalidone among resistant hypertension patients taking ≥ 4 medications. 20 Our study extends the current literature in a few additional ways. We examined trends in treatment of resistant hypertension after publication of the AHA recommendations, showing no increase in physician prescribing of recommended medications for resistant hypertension. Also, the nationally representative data on physicians' practice in NAMCS allows us to examine potential systemic variations in physicians' use of evidence-based treatment at the national level based on patient factors such as age, insurance status, and presence of comorbid conditions. Thiazide diuretic use was reported at less than 60 % of visits. Current guidelines recommend use of thiazide in resistant hypertension whenever possible. 3 This current level of thiazide use in resistant hypertension may be inappropriately low, but appropriate use is difficult to assess conclusively. Clinically appropriate reasons to avoid use of thiazides exist, including electrolyte abnormalities, orthostatic hypotension, and patient preference or nonadherence. 21, 22 In fact, the higher likelihood of adverse effects and contraindications (e.g. orthostatic hypertension) seen with older age plausibly explains the age association with lower thiazide use reported here. 23, 24 On the other hand, previous reports have suggested that physicians often fail to implement effective antihypertensive agents when warranted. [25] [26] [27] [28] [29] While NAMCS data cannot reliably help us distinguish between these explanations, systems that provide care for similarly older populations, such as the Veterans Health Administration (VHA), have been able to successfully increase thiazide use in their overall hypertensive patient population. 30 This suggests that there may be room for increased thiazide use among resistant hypertension patients in the U.S population. Longitudinal observational studies are needed to better assess appropriate use and identify potential strategies for safe increase of thiazide use in resistant hypertension. We observed a trend toward lower use of ACE-I and higher use of beta blockers, potentially suggestive of a departure from more effective therapies in management of resistant hypertension, although data about appropriateness is limited in this analysis. Ongoing monitoring of national data is warranted to assess for changes in practice patterns.
Physician use of aldosterone antagonists and chlorthalidone continues to be very uncommon, despite evidence of substantial improvement in BP control achieved by using these medications in resistant hypertension patients with uncontrolled BP. 6, 7, 31, 32 This considerable underutilization is not likely explained by patient factors or physician practice preferences because their use is too low to be subjected to significant variations. Low awareness of the efficacy of these medications is likely a contributory factor, but may also not fully explain the low utilization rate. The AHA recommendations for aldosterone antagonist use were only recently published, but the evidence for chlorthalidone has been known for quite some time. 10, 33 Why increasing the use of these medications has proven difficult is not well understood, although behavioral norms and entrenched practice patterns biased against their use may contribute to the challenges in increasing their use.
Implementation of clinical guidelines has historically been slow and uneven. 34, 35 Indeed, the use of thiazide diuretics did not increase from 1992 to 1995 after publication of JNC V guidelines recommending thiazides as a first choice antihypertensive treatment. 36 However, system-level and clinic-level interventions, such as providing feedback to physicians regarding their patterns of medication use, have successfully promoted more rapid adoption of guideline-recommended therapies. 3 4 Furthermore, clinical trials and integrated healthcare systems have achieved high BP control rates (60-80 %) 37, 38 through use of stepped-care hypertension management protocols with treatment algorithms implemented by nurses or pharmacists. 39 However, while these protocols have utilized accepted therapies for stage 1 and stage 2 hypertension, guidance for resistant hypertension has been more restricted and at times not consistent with those recommended by guidelines. 40, 41 Adding treatment recommendations specific to resistant hypertension in management protocols could lead to increased use of more effective medications. In fact, clinics specializing in treatment of resistant hypertension have achieved greater BP control through the use of guidelinerecommended medications. 42, 43 A focus on use of combination drugs could be especially effective in improving BP control in resistant hypertension patients. In addition to their efficacy in BP lowering and improving medication adherence, fixed-dose combinations may lead to increased use of the more effective medication classes for resistant hypertension. First, more frequent use of fixed-dose combinations would likely correspond with greater thiazide use, given that they often contain a thiazide diuretic. Only 5 % of aldosterone use noted in this analysis was as a component of the hydrochlorothiazide/ spironolactone pill (see Online Appendix), a combination that may maximize BP-lowering efficacy. 32 A new fixeddose combination that includes chlorthalidone is currently being investigated and may lead to greater use of chlorthalidone. 44 Some limitations should be considered in interpreting these results. First, the cross-sectional nature of the data precludes us from knowing whether a medication had been discontinued in the past because of patient preference or intolerance. The degree of underutilization reported here, however, is unlikely explained primarily by patient preference or intolerance. Second, our analysis relies on routine office-based BP readings. Although there is concern in the literature regarding the reliability of office BP thresholds and white coat hypertension leading to overdiagnosis and over-treatment of hypertension, office-based BP is still the current standard used for treatment. 19, 45, 46 Thirdly, NAMCS does not provide information on medication adherence dosage, or indications for medication use possibly leading to some misclassification of resistant hypertension as with prior observational analyses. 2 Knowledge of patient non-adherence may impact a physician's decision in prescribing or continuing that medication, but describing patient adherence is not the primary intent in this analysis, which is focused largely on physician behavior in the management of resistant hypertension. Lastly, since NAMCS abstractors could only list up to eight medications per visit, an antihypertensive medication may have not been listed; however, patients taking eight or more medications comprised less than 7 % of our study population. Furthermore a sub-analysis excluding these patients did not significantly change our estimates of medication use.
CONCLUSION
Our study documents continued widespread underutilization of effective medications for resistant hypertension that remains unchanged 2 years after publication of AHA guidelines. Increasing the use aldosterone antagonists and fixed-dose combination medications could significantly improve BP control in resistant hypertension. Employing treatment algorithms that encourage prescription of these medications could help achieve significantly greater BP control in this high-risk population.
